{"organizations": [], "uuid": "92d2610d2ebb04f406657a6492aac41cdab75938", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180308.html", "section_title": "Archive News &amp; Video for Thursday, 08 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-spimaco-signs-mou-with-astrazeneca/brief-spimaco-signs-mou-with-astrazeneca-idUSFWN1QP0ZR", "country": "US", "domain_rank": 408, "title": "BRIEF-SPIMACO Signs MoU With Astrazeneca", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.957, "site_type": "news", "published": "2018-03-08T13:56:00.000+02:00", "replies_count": 0, "uuid": "92d2610d2ebb04f406657a6492aac41cdab75938"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-spimaco-signs-mou-with-astrazeneca/brief-spimaco-signs-mou-with-astrazeneca-idUSFWN1QP0ZR", "ord_in_thread": 0, "title": "BRIEF-SPIMACO Signs MoU With Astrazeneca", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "astrazeneca", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 8 (Reuters) - SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORP:\n* SIGNS MOU WITH ASTRAZENECA, TARGETS INVESTMENT, TECHNOLOGY TRANSFER, MANUFACTURING RANGE OF PHARMACEUTICALS UNDER PROJECT OF PRODUCING MEDICINES FOR CANCER DISEASES\n* ESTIMATED COST FOR PROJECT OF PRODUCING MEDICINES FOR CANCER DISEASES BASED ON CURRENT STUDIES TO REACH 245 MILLION RIYALS\n* EXPECTS TO COMPLETE PROJECT BY END OF Q3 2019 Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-08T13:56:00.000+02:00", "crawled": "2018-03-09T14:32:37.053+02:00", "highlightTitle": ""}